NCT06424106 Effect of Glucagon on Fasting Insulin Secretion and Glucose Metabolism in Subjects Without Type 2 Diabetes
| NCT ID | NCT06424106 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Mayo Clinic |
| Condition | PreDiabetes |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2025-04-01 |
| Primary Completion | 2027-07-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 60 participants in total. It began in 2025-04-01 with a primary completion date of 2027-07-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Fasting hyperglycemia contributes disproportionately to nonenzymatic glycosylation and the microvascular complications of type 2 diabetes. However, little is known about the regulation of glucose concentrations in the fasting state relative to what is known about the postprandial state. The proposed experiment is part of a series of experiments designed to establish how glucagon and insulin interact with their receptors to control fasting glucose in health and in prediabetes.
Eligibility Criteria
Inclusion Criteria: * Individuals with normal or impaired fasting glucose and normal or impaired glucose tolerance Exclusion Criteria: * HbA1c less than 6.5% * Use of any glucose-lowering agents including metformin or sulfonylureas. * For female subjects: positive pregnancy test at the time of enrollment or study * History of prior upper abdominal surgery such as adjustable gastric banding, pyloroplasty and vagotomy. * Active systemic illness or malignancy. * Symptomatic macrovascular or microvascular disease.
Contact & Investigator
Adrian Vella, MD
PRINCIPAL INVESTIGATOR
Mayo Clinic
Frequently Asked Questions
Who can join the NCT06424106 clinical trial?
This trial is open to participants of all sexes, aged 25 Years or older, up to 65 Years, studying PreDiabetes. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06424106 currently recruiting?
Yes, NCT06424106 is actively recruiting participants. Contact the research team at Osmundson.Kimberly@mayo.edu for enrollment information.
Where is the NCT06424106 trial being conducted?
This trial is being conducted at Rochester, United States.
Who is sponsoring the NCT06424106 clinical trial?
NCT06424106 is sponsored by Mayo Clinic. The principal investigator is Adrian Vella, MD at Mayo Clinic. The trial plans to enroll 60 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.